Jonathan A. Ledermann, MD, and Ursula A. Matulonis, MD, on Olaparib Maintenance Monotherapy for Ovarian Cancer
2016 ASCO Annual Meeting
Jonathan A. Ledermann, MD, of Cancer Research UK and University College London Cancer Trials Centre, and Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, discuss findings on overall survival in patients with platinum-sensitive relapsed serous ovarian cancer receiving olaparib maintenance monotherapy (Abstract 5501).
Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discuss findings from this phase III trial of nivolumab combined with ipilimumab in treatment-naive patients with advanced disease (Abstract 9505).
Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advanced/metastatic disease (Abstract LBA4500).
Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, discusses the substantial overuse of aggressive medical care for younger patients at the end of life, despite ASCO recommendations (Abstract LBA10033).
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as well as localized disease (Abstracts 5001, 5003, 5023, and 5021).
Eric Roeland, MD, of the University of California, San Diego, and Jennifer S. Temel, MD, of Massachusetts General Hospital, discuss findings that showed the benefits of offering palliative care integrated with oncology care (Abstracts 10003 and 10131).
